The Lynch syndrome (LS) is an inherited cancer syndrome showing a preponderance of colorectal cancer (CRC) in context with endometrial cancer and several other extracolonic cancers, which is due to pathogenic mutations in the mismatch repair (MMR) genes, MLH1 , MSH2 , MSH6 , and PMS2 . Some families were found to show a LS phenotype without an identifi ed MMR mutation, although there was microsatellite instability and absence of MSH2 expression by immunohistochemistry. Studies of a subset of these families found a deletion at the 3 ′ end of the epithelial cell adhesion molecule ( EPCAM ) gene, causing transcription read-through resulting in silencing of MSH2 through hypermethylation of its promoter. The tumor spectrum of such families appears to differ from classical LS.
INTRODUCTION
Th e Lynch syndrome (LS) predisposes to colon cancer and several extracolonic cancers, the most common of which is endometrial cancer. Th ese are caused by mutations in the DNA mismatch repair (MMR) genes MLH1 , MSH2 , MSH6 , and PMS2 . A subset of families with phenotypes consonant with LS, including microsatellite instability and abnormal MMR immunohistochemistry have been found to harbor a deletion at the 3 ′ end of the gene encoding epithelial cell adhesion molecule ( EPCAM ; previously referred to as TACSTD1 ) ( 1 -6 ) . Th e tumors with EPCAM mutations showed high-level microsatellite instability; immunohistochemistry tests disclosed a loss of MSH2 protein, with no identifi able mutation in the MSH2 gene ( 1, 3 ) . EPCAM mutations were found to cosegregate with the LS phenotype in a considerable fraction (19 % ) of LS families that lacked MLH1 / MSH2 mutations ( 3 ) and to account for at least 2.3 % of explained MSH2-defi cient families ( 5 ) . EPCAM is located immediately 5 ′ of MSH2 and deletion of its termination signal allows transcription to follow through across the MSH2 promoter leading to promoter hypermethylation and gene silencing. In EPCAM deletion-positive subjects, the risk of developing colorectal cancer (CRC) was shown to be comparable to that of carriers of a MSH2 mutation. However, their risk of developing endometrial cancer was lower than in MSH2 mutation carriers, and appeared to be restricted to carriers of deletions that extend close to the MSH2 gene ( 7 ) .
Family R ( Figure 1 ) is a large LS family that was referred to the Creighton research group 35 years ago by the proband ' s surgeon, who knew that CRC was highly prevalent throughout fi ve generations of the family. Study of Family R contributed to the template for the classic description of LS and it was the fourth hereditary CRC family studied by Dr Lynch. Family R was fi rst reported at a conference in 1976 ( 8 ) , and further updated in 1977 ( 9 ) . Repeated comprehensive DNA testing by several groups failed to fi nd a mutation in a MMR gene until EPCAM deletions were reported to cause LS ( 1 ) .
In this study we show that Family R carries the same EPCAM mutation as Dutch Family A, the fi rst family in which a 3 ′ end EPCAM deletion was recognized as the cause of MSH2-defi cient tumors due to hypermethylation of the MSH2 promoter ( 1 ). Th ese two families are the largest common ancestor pedigrees reported to date. Analysis of their tumor spectrum is used to determine the risk of extracolonic tumors in carriers of this specifi c EPCAM mutation.
METHODS

Subjects
Th is study was approved by the Institutional Review Boards of the institutions involved.
USA Family R . Contact was continually maintained with Family R through telephone calls, correspondence, and personal contact through several educational family information services (FISs) ( 10 ) . Th e FIS is comprised of a gathering of as many family members as wish to attend the meeting so that they can benefi t from an informal educational coverage of the " family disease, " including its diagnosis, the signifi cance of a deleterious germline mutation, and its phenotypic features. It then deals with the patient ' s risk of developing CRC with focus upon targeted screening recommendations based upon a patient ' s position in the pedigree. Th e proband ( Figure 1 , III-4 ) and several other family members were instrumental in gathering information from and distributing information to the family. Genetic counseling was based upon the compelling evidence for a Mendelian autosomal dominant pattern of CRC throughout the family in concert with its striking clinical and pathology features. Given these fi ndings, fi rst-degree relatives of individuals who developed CRC were strongly encouraged to undergo colonoscopy every other year starting at age 20 -25 and then annually beginning at age 40 ( 8,11 -14 ) . At the time of the FIS, the initial fi nding of a lack of endometrial cancer risk had not yet been confi rmed and patients were recommended standard LS endometrial cancer surveillance and consideration of prophylactic hysterectomy.
Following the discovery of MMR mutations in LS families in the mid-1990s ( 15 -20 ) , we began DNA testing on the most genetically informative members of Family R, namely those with early onset CRC and / or metachronous CRC; however, we were unable to identify a MMR gene mutation.
In October 2009, the EPCAM mutation c.859-1462_ * 1999del was identifi ed in a member of Family R ( Figure 1, V-6 ). Shortly aft erward, we held another FIS wherein > 70 Family R members attended in order to learn about this new fi nding and how it might impact them. Family members for whom we did not have a stored sample were invited to provide blood for testing. Forty-seven DNA samples were tested for the EPCAM mutation. Another FIS was held in March 2010 in order to provide individuals with their DNA test results in private genetic counseling sessions. Th is FIS also gave other family members an opportunity to provide a DNA sample for testing. All living relatives found it acceptable to include their genotyping information in the pedigree. Dutch Family A . Th e proband of the Dutch Family A ( Figure 2 ) visited the outpatient clinic for family cancer of the Radboud University Nijmegen Medical Centre, because he developed two colorectal carcinomas at age 47. He was the fi rst patient in whom a deletion of the 3 ′ end of EPCAM was observed ( 1 ). Th is deletion was also detected in his son, who visited our outpatient clinic because he developed an MSH2-defi cient CRC at age 18. Th is deletion was also present in three more distantly related family members aff ected with CRC, who had been contacted by the proband and underwent genetic counseling and testing for this mutation. Aft er the pathogenicity of the deletion was proven, presymptomatic testing was off ered to other family members using routine procedures by which the information is disseminated by contact persons within the family. Individuals in the pedigree were deidentifi ed to protect their privacy without loss of the scientifi c information.
Laboratory methods
Immunohistochemistry for the MMR proteins was performed as previously described ( 1 ) . In Family R, EPCAM deletion analysis was performed on DNA extracted from peripheral blood using a commercially available MLPA (multiplex ligation-dependent probe amplifi cation kit; P072 version 6, MRC Holland, Amsterdam, Th e Netherlands) as per the manufacturer ' s instructions. Th is kit contains oligonucleotide probes targeting EPCAM exons 3, 8, 9, and two probes in the intervening region between EPCAM and MSH2 : one 3 kb downstream of EPCAM and one 2.5 kb upstream from the MSH2 gene. In Family A, the mutation was tested for using a deletion-specifi c polymerase chain reaction as previously described ( 1 ).
RESULTS
USA Family R
Overall, DNA testing for the EPCAM mutation in Family R showed that 22 individuals were positive, 16 were obligate mutation carriers, and 42 were negative ( Figure 1 
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Extracolonic Tumors Rare With EPCAM Deletion two breast, one lung, and one pancreas carcinoma. Th ese latter four tumors were not available for further analysis. No endometrial cancers were observed.
Common ancestor
Both families share the 3 ′ end EPCAM deletion c.859-1462_ * 1999del. Single nucleotide polymorphism array-based genotyping showed that a large genomic region surrounding the deletion (haploblock) was shared by members of both Family R and Family A ( Figure 3 ). Th ese fi ndings indicate that the EPCAM mutations in Family R and Family A originate from a common ancestor. Th e same mutation has been detected in 15 other Dutch probands ( 5,7 ).
DISCUSSION
Th e extended kindreds described here are among the largest reported in medical genetics. Th e breadth and size of the kindreds, endometrial cancer and this individual was found to be negative for the EPCAM mutation. Th ere were no cases of ovarian cancer. Th ree family members had small bowel cancer; of these, one tested positive for the EPCAM mutation, one tested negative, and the third has not been tested. Th e tumor tissue from the small bowel cancer from the confi rmed EPCAM mutation carrier was available and showed loss of MSH2 and MSH6 expression. Th ree family members had upper uroepithelial tract cancer; none of them has been tested.
Dutch Family A
For the Dutch Family A, clinical data were collected for all family members who underwent genetic testing ( Table 2 ). All 10 patients with CRC were carriers of the mutation. Th e mean age at diagnosis of their fi rst CRC was 47 years (range 18 -70 years). Within this group, the only extracolonic cancers detected were one MSH2-defi cient duodenal cancer, one MSH2-profi cient urothelial carcinoma, and the number of related cancers, is testament to the potential impact of a single mutation event. Over the years, genetic epidemiology research has resulted in a signifi cant expansion of knowledge on what was initially termed the " cancer family syndrome, " ( 9 ) subsequently called hereditary nonpolyposis CRC, and now referred to as LS ( 11, 12, 21 ) . Specifi cally, diagnostic parameters such as the occurrence of cancer of diverse anatomic sites, its pattern of cancer combinations, early age of cancer onset, pathological features, MMR penetrance, accelerated carcinogenesis, and survival may vary enormously within and between families. Th e Amsterdam Criteria ( 22, 23 ) were developed two decades ago in an attempt to better describe and defi ne LS families. However, only about 60 % of families fulfi lling the Amsterdam Criteria manifest MMR germline mutations consonant with LS ( 24 ) . A subset of the remaining 40 % include familial CRC type X ( 25 ), while the more recently discovered EPCAM mutation explains part of the remainder ( 1 -6 ).
Site-specifi c CRC and EPCAM
Th e tumors of EPCAM deletion carriers show loss of expression of MSH2 and MSH6, a pattern also seen with MSH2 germline mutation carriers. Nowadays, the majority of clinical laboratories that are testing for MMR gene mutations test for EPCAM deletions as relevant probes for the EPCAM gene are included in the MLPA kit used for the analysis of MSH2 deletions. Th e medical and genetic literature shows that MSH2 mutation carriers develop extracolonic cancers, especially endometrial cancer, more frequently than carriers of MLH1 mutations ( 3, 11, 12 ) . Deletions in EPCAM result in hypermethylation and tissue-restricted silencing of MSH2 ( 1 ), which is dependent on the expression pattern of the EPCAM gene. Th is fi nding probably explains the rare incidence of extracolonic cancers in the subset of EPCAM mutation carriers in both extended families described here and multiple other families described earlier ( 7 ) . Th ere is little experimental evidence on the relative expression of EPCAM in various tissues. We postulate that at least during early stages of endometrium carcinogenesis, EPCAM is not suffi ciently expressed and therefore the MSH2 promoter is not effi ciently silenced, leading to a lower endometrial cancer risk than observed in MSH2 mutation carriers. In our recent collaborative study of specifi c EPCAM deletion genotype / phenotype correlations, no endometrial cancer was observed in 62 female EPCAM deletion carriers with mutations distant from the MSH2 promoter ( 7 ). Endometrial cancer was observed in only 3 out of 30 carriers with larger EPCAM deletions that extend close to the MSH2 promoter. In line with this, the family history of the total 12 additional EPCAM deletion families shows no endometrial cancers ( 6, 26 ) . Unspecifi ed gynecologic cancers were noted in only one of these families, which has a deletion extending close to the MSH2 promoter ( 6 ) . A large collaborative study is needed to further refi ne the endometrial cancer risk with respect to the size and location of 
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The presence of a small 3 ′ EPCAM deletion has resolved the high incidence of microsatellite instability-high tumors in two large LS families that were unexplained for decades. The lack of endometrial cancer in these families marks further understanding of the differences in the LS phenotype that will lead to more effective cancer control. The discovery of EPCAM deletions and their impact on hereditary cancer is likely the tip of the proverbial iceberg with respect to mutations that affect known disease causing genes indirectly. Large, well-characterized families as described here can be instrumental in unraveling such novel genetic mechanisms, which will increase our understanding of gene regulation and may provide a multitude of families with important information for surveillance ( 11, 12 ) .
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Th ree cases of small bowel adenocarcinoma, two occurring in the duodenum and one in the jejunum, were seen in Families R and A. Other small bowel cancers, located in the duodenum and ileum, have been identifi ed in EPCAM mutation carriers ( 1,4,7 ) . Th e timing and frequency of small bowel cancer surveillance in EPCAM mutation carriers require further study before an informed recommendation can be made.
Genetic counseling implications
LS families with EPCAM mutations now have a rational explanation for their signifi cantly increased cancer susceptibility. Th erefore, instead of receiving an " uninformative negative " MSH2 mutation test result, they are given results based on a pathogenic EPCAM mutation. Family members found not to harbor the EPCAM mutation do not have an increased lifetime risk for cancer and thus can follow general population screening guidelines. Conversely, those found to have the EPCAM pathogenic mutation will be advised to follow the high-risk LS CRC surveillance recommendations. Having a defi nitive diagnosis has increased acceptance of LS cancer screening recommendations ( 11, 12 ) .
Limitations for implementing diagnosis and cancer control in LS
LS is frequently under-recognized due to small families, physicians not taking a detailed family history for cancer, or unawareness by patients of their own family history ( 28 ) . Although routine microsatellite instability testing at the initiative of the pathologist in CRC diagnosed before age 50 can signifi cantly enhance recognition of LS patients ( 29 ) , this procedure has been implemented in only relatively few centers. In the next few years, many evolving genetic and genomic technologies devoted to cancer risk assessment will reach our daily clinical practice, heralding and fi nally implementing the era of personalized medicine ( 30 ) . It will be important for clinicians to recognize the oft en profound cancer control potential when attention is paid to the family history including early age at cancer diagnosis and, when necessary, referral is made to genetic centers that off er high levels of expertise for DNA testing when appropriate. Th is permits the physician to apply appropriate surveillance programs to patients who require this, and to avoid inappropriate surveillance in at-risk family members who did not inherit the pathological allele. Family R and Family A, with the identifi cation of their EPCAM mutation, is one such example.
